ResearcherSheng Jing HospitalActive in the last 2 years

Wei Yao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5125918177. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

Emerging Chimeric Antigen Receptor-Immune Cell Therapy for Pancreatic Cancer: Mechanisms, Clinical Advances, and Future Perspectives. Last author DOI 10.32604/or.2025.073554 ↗
B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.110889 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shuo Wang · 1 shared paper, 2026 · strength 0.50
- Paper Emerging Chimeric Antigen Receptor-Immune Cell Therapy for Pancreatic Cancer: Mechanisms, Clinical Advances, and Future… DOI 10.32604/or.2025.073554 ↗
Xin Zhang · 1 shared paper, 2024 · strength 0.31
- Paper B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer. DOI 10.1016/j.isci.2024.110889 ↗
Yuhe Lin · 1 shared paper, 2024 · strength 0.31
- Paper B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer. DOI 10.1016/j.isci.2024.110889 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.